RCD方案在多发性骨髓瘤维持治疗中的临床研究

目的 对来那度胺联合环磷酰胺,地塞米松(RCD方案)在多发性骨髓瘤维持治疗中的临床研究.方法 78例多发性骨髓瘤患者,以随机信封分组法分为参比组和试验组,每组39例.参比组应用常规化疗方案治疗.试验组应用RCD方案治疗.比较两组患者治疗后的相关指标(M-蛋白、 β2-微球蛋白、CD4+、CD4+/CD8+)、临床疗效、...

Clinical study of RCD regimen in maintenance treatment of multiple myeloma

Objective To study the clinical effect of Revlimid,cyclophosphamide and dexamethasone(RCD regimen)in maintenance treatment of multiple myeloma.Methods A total of 78 patients with multiple myeloma were divided into reference group and test group by random envelope grouping,with 39 cases in each group.The reference group was treated with conventional chemotherapy regimen,and the test group was treated with RCD regimen.The related indicators(M-protein,β₂-microglobulin,CD4⁺,CD4⁺/CD8⁺),clinical efficacy,and occurrence of adverse drug reactions after treatment were compared between the two groups.Results After treatment,the M-protein(17.39±6.08)g/L and β₂-microglobulin(1.61±0.36)mg/L of the test group were lower than(23.54±8.37)g/L and(2.25±0.63)mg/L of the reference group,and the CD4⁺(45.24±5.13)%,CD4⁺/CD8⁺(1.78±0.51)were higher than(35.92±4.79)%,(1.32±0.44)of the reference group,and the difference was statistically significant(P<0.05).The total effective rate of treatment 87.18%in the test group was higher than 64.10%in the reference group,and the difference was statistically significant(P<0.05).The incidence of neuropathy,lethargy,and constipation of the test group was lower than that of the reference group,and the incidence of reduced platelet count and neutrophil count was higher than that of the reference group,and the differences were statistically significant(P<0.05).Conclusion In the treatment of patients with multiple myeloma,the use of RCD regimen can improve the relevant indicators of the patient,improve the clinical efficacy,and reduce the incidence of adverse drug reactions such as neuropathy,lethargy,and constipation.It is worthy of clinical promotion.